Initially, strong CTGF immunoreactivity was observed in the vicinity of Aβ plaques and NFTs in AD postmortem brains, which mainly appeared in the hippocampus, entorhinal cortex, and temporal cortex and increased with the progression of the disease8,9. This evidence concerns the gene CCN2 and Alzheimer disease.